Deuffic-Burban, Sylvie

Publishing since 2002 (Junior)

Has published 20 publications in 8 years

Number of publications published per year by Deuffic-Burban, Sylvie. (Source : PubMed)

Distribution of publications types for Deuffic-Burban, Sylvie. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, Louvet A, Roudot-Thoraval F, Mathurin P. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.  Hepatology  2009;50;5  
•  Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives.  Stat Methods Med Res  2009;18;3  
•  Deuffic-Burban S, Abiteboul D, Lot F, Branger M, Bouvet E, Yazdanpanah Y. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.  Gut  2009;58;1  
•  Champenois K, Deuffic-Burban S, Cotte L, André P, Choisy P, Ajana F, Bocket L, Yazdanpanah Y. Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.  J. Med. Virol.  2008;80;11  
•  Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, Boitard J, Henrion J, Yazdanpanah Y, Mathurin P. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France.  J. Hepatol.  2008;49;2  
•  Champenois K, Bocket L, Deuffic-Burban S, Cotte L, André P, Choisy P, Yazdanpanah Y. Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.  AIDS  2008;22;9  
•  de la Tribonnière X, Broly F, Deuffic-Burban S, Bocket L, Ajana F, Viget N, Melliez H, Mouton Y, Yazdanpanah Y. ABCB1 allele polymorphism is associated with virological efficacy in naïve HIV-infected patients on HAART containing nonboosted PIs but not boosted PIs.  HIV Clin Trials  2008;9;3  
•  Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.  J. Viral Hepat.  2007;14;2  
•  Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, Divi N, Freedberg KA, Anglaret X, Yazdanpanah Y. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.  Eur. J. Epidemiol.  2007;22;10  
•  Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, Gabillard D, Seyler C, Freedberg KA, Anglaret X. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.  Antivir. Ther. (Lond.)  2007;12;4  

[ See timeline ] [ See all publications ]